Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02908906 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

A Phase 1 study of Neoplasms, sponsored by Janssen Research & Development.

Active
Registry status
Phase 1
Development phase
413
Enrollment target
20
Study locations

NCT02908906 is a Phase 1 study of Neoplasms that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 413 participants, below the 1,619-participant average among 158 other Neoplasms trials with a reported enrollment target (74% lower). The trial reports 20 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02908906, a Phase 1 study of Neoplasms, is active but no longer recruiting, sponsored by Janssen Research & Development.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
413 participants
Enrollment target
20
Study locations

Study Summary

The Primary purpose of this study is to identify the recommended Phase 2 dose \[RP2D(s)\] for JNJ-63723283 in Part 1, to assess the anti-tumor activity of JNJ-63723283 at the RP2D(s) in participants with selected advanced cancers including non-small-cell lung cancer (NSCLC), melanoma, renal, bladder, small-cell lung cancer (SCLC), gastric/esophageal cancer, and high-level microsatellite instability (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer (CRC) in Part 2, to determine one or more additional RP2Ds in Parts 3 and 4.

Conditions Studied

Neoplasms

Interventions

  • DRUG JNJ-63723283

Study Locations (20)

Other

  • - Chisinau
  • - Bialystok
  • - Warsaw
  • - Moscow
  • - Pyatigorsk
  • - Saint Petersburg
  • - Badalona
  • - Barcelona
  • - Madrid
  • - Málaga
  • - Pamplona
  • - Seville
  • - Valencia
  • - Gothenburg
  • - Glasgow
  • - London
  • - Manchester
  • - Newcastle upon Tyne

Missouri

  • - St Louis

Pennsylvania

  • - Pittsburgh

Trial Details

FieldValue
Enrollment Target 413 participants
Start Date 2016-11-21
Est. Completion 2026-12-31
Phase Phase 1

Sponsor

Janssen Research & Development

593 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02908906

The ClinicalTrials.gov registry entry for NCT02908906 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 413 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,619-participant average among 158 other Neoplasms trials with a reported enrollment target (74% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which JNJ-63723283 is the first listed.

NCT02908906 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Other, Missouri, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02908906 about?

NCT02908906 is a clinical study titled "A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers". The Primary purpose of this study is to identify the recommended Phase 2 dose \[RP2D(s)\] for JNJ-63723283 in Part 1, to assess the anti-tumor activity of JNJ-63723283 at the RP2D(s) in participants with selected advanced cancers including non-small-cell lung cancer (NSCLC), melanoma, renal, bladder...

What is the current status of trial NCT02908906?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 413 participants. The study started on 2016-11-21. Estimated completion is 2026-12-31.

What conditions does trial NCT02908906 study?

This clinical trial studies the following conditions: Neoplasms.

What interventions are being tested in trial NCT02908906?

The interventions under investigation include: JNJ-63723283 (DRUG).

Who is sponsoring clinical trial NCT02908906?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02908906 being conducted?

This trial has 20 study locations across Missouri, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasms

All registered trials for this condition

Missouri

All trials with a study site in Missouri

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.